Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE (Tables)

FAIR VALUE (Tables)

6 Months Ended

Jun. 30, 2017

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of June 30, 2017 and December 31, 2016:

	June 30, 2017
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
February 2013 Public Offering Warrants	$	—	$	—	$	18,600	$	18,600
August 2014 Warrants		—		101,000		—		101,000
Total	$	—	$	101,000	$	18,600	$	119,600

	December 31, 2016
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
February 2013 Public Offering Warrants	$	—	$	—	$	27,125	$	27,125
August 2014 Warrants		—		100,000		—		100,000
Total	$	—	$	100,000	$	27,125	$	127,125

Schedule Of Changes In Fair Value Warrants Classified Level Three [Table Text Block]

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy:

	Six Months Ended		Twelve Months Ended
	June 30, 2017		December 31, 2016
Beginning balance – Fair value	$	27,125	$	2,067,000
Reclassification to equity for warrants that are no longer derivative liabilities		—		(1,392,429)
Gain on derivatives resulting from change in fair value or extinguishment		(8,525)		(647,446)
Ending balance – Fair value	$	18,600	$	27,125

2013 Warrants [Member]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

The following table summarizes the modified option-pricing assumptions used:

	Six Months Ended			Twelve Months Ended
	June 30, 2017			December 31, 2016
Volatility		76	%		92.72-134	%
Risk-free interest rate		1.21	%		0.53-1.15	%
Expected life (years)		0.64			1.14-1.89
Dividend		0	%		0	%

2015 Warrants [Member]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

The following table summarizes the modified option-pricing assumptions used for the period they were considered financial instruments:

	Twelve Months Ended December 31, 2016
Volatility		89.73	%
Risk-free interest rate		1.65	%
Expected life (years)		4.50
Dividend		0	%